BR9205645A - Derivados de 2,4-diaminoquinazolinas para aumentar a atividade antitumoral - Google Patents

Derivados de 2,4-diaminoquinazolinas para aumentar a atividade antitumoral

Info

Publication number
BR9205645A
BR9205645A BR9205645A BR9205645A BR9205645A BR 9205645 A BR9205645 A BR 9205645A BR 9205645 A BR9205645 A BR 9205645A BR 9205645 A BR9205645 A BR 9205645A BR 9205645 A BR9205645 A BR 9205645A
Authority
BR
Brazil
Prior art keywords
antitumor activity
increase antitumor
diaminoquinazoline derivatives
diaminoquinazoline
derivatives
Prior art date
Application number
BR9205645A
Other languages
English (en)
Inventor
Jotham W Coe
Anton F J Fliri
Takushi Kaneko
Eric R Larson
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of BR9205645A publication Critical patent/BR9205645A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
BR9205645A 1991-02-20 1992-01-08 Derivados de 2,4-diaminoquinazolinas para aumentar a atividade antitumoral BR9205645A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US65792291A 1991-02-20 1991-02-20
PCT/US1992/000028 WO1992014716A1 (en) 1991-02-20 1992-01-08 2,4-diaminoquinazolines derivatives for enhancing antitumor activity

Publications (1)

Publication Number Publication Date
BR9205645A true BR9205645A (pt) 1994-06-07

Family

ID=24639196

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9205645A BR9205645A (pt) 1991-02-20 1992-01-08 Derivados de 2,4-diaminoquinazolinas para aumentar a atividade antitumoral

Country Status (23)

Country Link
EP (1) EP0572437B1 (pt)
JP (1) JPH06500117A (pt)
KR (1) KR930703270A (pt)
CN (1) CN1064271A (pt)
AT (1) ATE121735T1 (pt)
AU (1) AU655798B2 (pt)
BR (1) BR9205645A (pt)
CA (1) CA2101542A1 (pt)
CZ (1) CZ387292A3 (pt)
DE (2) DE9290018U1 (pt)
DK (1) DK0572437T3 (pt)
ES (1) ES2071484T3 (pt)
FI (1) FI933656A0 (pt)
HU (1) HUT64755A (pt)
IE (1) IE920522A1 (pt)
IL (1) IL100942A0 (pt)
MX (1) MX9200675A (pt)
NO (1) NO932954L (pt)
NZ (1) NZ241627A (pt)
PT (1) PT100132A (pt)
WO (1) WO1992014716A1 (pt)
YU (1) YU17092A (pt)
ZA (1) ZA921911B (pt)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU661533B2 (en) * 1992-01-20 1995-07-27 Astrazeneca Ab Quinazoline derivatives
ES2049659B1 (es) * 1992-10-08 1994-10-16 Ici Plc Una composicion farmaceutica a base de derivados de quinazolina con actividad anti-cancerigena.
GB9323290D0 (en) * 1992-12-10 1994-01-05 Zeneca Ltd Quinazoline derivatives
GB9314893D0 (en) * 1993-07-19 1993-09-01 Zeneca Ltd Quinazoline derivatives
IL112248A0 (en) 1994-01-25 1995-03-30 Warner Lambert Co Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them
IL112249A (en) 1994-01-25 2001-11-25 Warner Lambert Co Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds
DE4429026C2 (de) * 1994-08-16 1995-11-16 Mueller Wolfgang Inlay-Entfernungsinstrumentarium für Totalendoprothese
GB9424233D0 (en) * 1994-11-30 1995-01-18 Zeneca Ltd Quinazoline derivatives
GB9508535D0 (en) * 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivative
GB9508565D0 (en) * 1995-04-27 1995-06-14 Zeneca Ltd Quiazoline derivative
GB9508538D0 (en) * 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
WO1996033977A1 (en) * 1995-04-27 1996-10-31 Zeneca Limited Quinazoline derivatives
GB9508537D0 (en) * 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
AU7692896A (en) * 1995-12-01 1997-06-27 Novartis Ag Quinazolin-2,4-diazirines as NPY receptor antagonist
GB9624482D0 (en) * 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
CZ291386B6 (cs) 1996-02-13 2003-02-12 Zeneca Limited Chinazolinové deriváty jako inhibitory VEGF, způsob jejich přípravy a farmaceutický prostředek, který je obsahuje
GB9603095D0 (en) 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
GB9603097D0 (en) * 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline compounds
US6291455B1 (en) 1996-03-05 2001-09-18 Zeneca Limited 4-anilinoquinazoline derivatives
GB9607729D0 (en) * 1996-04-13 1996-06-19 Zeneca Ltd Quinazoline derivatives
GB9707800D0 (en) 1996-05-06 1997-06-04 Zeneca Ltd Chemical compounds
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
NZ518028A (en) 1999-11-05 2004-03-26 Astrazeneca Ab Quinazoline derivatives as VEGF inhibitors
AU2001240150A1 (en) * 2000-03-13 2001-09-24 Chemrx Advanced Technologies, Inc. Quinazoline synthesis
SI1274692T1 (sl) 2000-04-07 2006-12-31 Astrazeneca Ab Kinazolinske spojine
WO2003055866A1 (en) * 2001-12-21 2003-07-10 Bayer Pharmaceuticals Corporation Quinazoline and quinoline derivative compounds as inhibitors of prolylpeptidase, inducers of apoptosis and cancer treatment agents
CN1984660B (zh) * 2003-07-03 2010-12-15 美瑞德生物工程公司 作为天冬氨酸特异性半胱氨酸蛋白酶活化剂和细胞程序死亡诱导剂的4-芳基氨基-喹唑啉
WO2006074147A2 (en) * 2005-01-03 2006-07-13 Myriad Genetics, Inc. Nitrogen containing bicyclic compounds and therapeutical use thereof
US8309562B2 (en) 2003-07-03 2012-11-13 Myrexis, Inc. Compounds and therapeutical use thereof
JP2007269629A (ja) * 2004-06-21 2007-10-18 Astellas Pharma Inc キナゾリン誘導体
CA2573103A1 (en) * 2004-07-06 2006-02-09 Angion Biomedica Corporation Quinazoline modulators of hepatocyte growth factor / c-met activity for the treatment of cancer
US8258145B2 (en) 2005-01-03 2012-09-04 Myrexis, Inc. Method of treating brain cancer
CA2592971A1 (en) * 2005-01-03 2006-07-13 Myriad Genetics Inc. Method of treating brain cancer
JP2009518359A (ja) * 2005-12-07 2009-05-07 ノイロサーチ アクティーゼルスカブ 新規なキナゾリン−２，４−ジアミン誘導体及び小コンダクタンスカルシウム依存性カリウムチャネルの調節剤としてのそれらの使用
CN101100466B (zh) 2006-07-05 2013-12-25 天津和美生物技术有限公司 不可逆蛋白质酪氨酸磷酰化酶抑制剂及其制备和应用
WO2008086462A2 (en) * 2007-01-11 2008-07-17 Wyeth AMINO-SUBSTITUTED QUINAZOLINE DERIVATIVES AS INHIBITORS OF β-CANTENIN/TCF-4 PATHWAY AND CANCER TREATMENT AGENTS
CA2691932A1 (en) * 2007-06-27 2008-12-31 Summit Corporation Plc Use of compounds for preparing anti-tuberculosis agents
KR20130128308A (ko) * 2010-05-07 2013-11-26 캘리포니아 인스티튜트 오브 테크놀로지 이행 소포체 ａｔｐ아제의 저해를 위한 방법 및 조성물
US11318137B2 (en) * 2017-05-17 2022-05-03 Vanderbilt University Quinazoline compounds as modulators of Ras signaling

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3635979A (en) * 1969-09-29 1972-01-18 Pfizer Certain 6- and/or 7-alkoxy-substituted-2 4-bis(disubstituted amino) quinazolines
IL88507A (en) * 1987-12-03 1993-02-21 Smithkline Beckman Intercredit 2,4-diaminoquinazolines, process for their preparation and pharmaceutical compositions comprising them
AU610328B2 (en) * 1987-12-03 1991-05-16 Smithkline Beckman Intercredit B.V. 2,4- diaminoquinazoline derivatives

Also Published As

Publication number Publication date
ZA921911B (en) 1993-08-19
FI933656A (fi) 1993-08-19
JPH06500117A (ja) 1994-01-06
NO932954D0 (no) 1993-08-19
AU655798B2 (en) 1995-01-12
CA2101542A1 (en) 1992-08-21
EP0572437A1 (en) 1993-12-08
PT100132A (pt) 1993-05-31
DK0572437T3 (da) 1995-07-03
DE69202243T2 (de) 1995-08-31
DE9290018U1 (de) 1993-10-14
IL100942A0 (en) 1992-11-15
DE69202243D1 (de) 1995-06-01
EP0572437B1 (en) 1995-04-26
CN1064271A (zh) 1992-09-09
WO1992014716A1 (en) 1992-09-03
KR930703270A (ko) 1993-11-29
ATE121735T1 (de) 1995-05-15
FI933656A0 (fi) 1993-08-19
HU9302384D0 (en) 1993-11-29
NZ241627A (en) 1993-06-25
AU1184892A (en) 1992-09-15
MX9200675A (es) 1992-08-01
ES2071484T3 (es) 1995-06-16
NO932954L (no) 1993-08-19
CZ387292A3 (en) 1994-04-13
YU17092A (sh) 1994-12-28
HUT64755A (en) 1994-02-28
IE920522A1 (en) 1992-08-26

Similar Documents

Publication Publication Date Title
BR9205645A (pt) Derivados de 2,4-diaminoquinazolinas para aumentar a atividade antitumoral
BR9107070A (pt) Processo para a preparação de derivados de quinazolina uteis para melhorar a atividade antitumoral.
IN170909B (pt)
ES2054778T3 (es) Complejos de 1,2-bis (aminometil) ciclobutano-platino.
ES2068714T3 (es) Derivados de pirimidina para aumentar la actividad antitumoral.
ATE311399T1 (de) 2'-deoxy-4'-thioribonucleoside als antivirale und antikrebsmittel
DE59101256D1 (de) Gleiskörper.
CA1265160C (en) GEM-DIHALOGENO- AND GEM-TETRAHALOGENO-1,12-DIAMINO-4,9-DIAZA-DODECANE
IE862894L (en) Pharmaceutical compositions

Legal Events

Date Code Title Description
EG Technical examination (opinion): publication of technical examination (opinion)
FC Decision: refusal
FC Decision: refusal